Docetaxel added to androgen deprivation therapy (ADT) was the most cost-effective first-line regimen for patients with homologous recombination repair–altered metastatic hormone-sensitive prostate ...

Significantly less progression, especially unstable lesions, with relugolix versus leuprol ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

ADT with leuprolide was tied to increased coronary plaque vs relugolix in prostate cancer. What does this mean for CV risk?

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

In a pooled analysis, longer duration of androgen deprivation therapy (ADT) was associated with nonlinear improvements in outcomes in men with prostate cancer receiving definitive radiotherapy.

Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.

—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...

Metformin did not prevent development of metabolic syndrome in men receiving androgen deprivation therapy for prostate cancer in a phase III trial. Metformin was associated with improvement in weight, ...